Best Practice & Research Clinical Anaesthesiology
Volume 21, Issue 1 , Pages 15-30 , March 2007

Update on the role of non-opioids for postoperative pain treatment

  • Stephan A. Schug, MD FANZCA FFPMANZCA (Professor)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +61 8 9224 0201; Fax: +61 8 9224 0279.

References 

  1. White PF. The changing role of non-opioid analgesic techniques in the management of postoperative pain. Anesthesia and Analgesia. 2005;101(5 supplement):S5–S22
  2. Brune K, Zeilhofer HU. Antipyretic analgesics: basic aspects. In:  McMahon SB,  Koltzenburg M editor. Wall and Melzack's Textbook of Pain. Amsterdam: Elsevier; 2006;
  3. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature: New biology. 1971;231(25):232–235
  4. Samad TA, Moore KA, Sapirstein A, et al. Interleukin-1beta-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature. 2001;410(6827):471–475
  5. Woolf CJ, Salter MW. Neuronal plasticity: increasing the gain in pain. Science. 2000;288(5472):1765–1769
  6. Brune K. The early history of non-opioid analgesics. Acute Pain. 1997;1(1):33–40
  7. Barden J, Edwards J, Moore A, McQuay H. Single dose oral paracetamol (acetaminophen) for postoperative pain. Cochrane Database of Systematic Reviews. 2004;(1):CD004602
  8. Bonnefont J, Courade JP, Alloui A, Eschalier A. Antinociceptive mechanism of action of paracetamol. Drugs. 2003;63(Spec No 2):1–4
  9. Schwab JM, Schluesener HJ, Laufer S. COX-3: just another COX or the solitary elusive target of paracetamol?. Lancet. 2003;361(9362):981–982
  10. Warner TD, Mitchell JA. Cyclooxygenase-3 (COX-3): filling in the gaps toward a COX continuum?. Proceedings of the National Academy of Sciences of the United States of America. 2002;99(21):13371–13373
  11. Botting R. COX-1 and COX-3 inhibitors. Thrombosis Research. 2003;110(5-6):269–272
  12. Botting RM. Mechanism of action of acetaminophen: is there a cyclooxygenase 3?. Clinical Infectious Diseases. 2000;31(supplement 5):S202–S210
  13. Pelissier T, Alloui A, Caussade F, et al. Paracetamol exerts a spinal antinociceptive effect involving an indirect interaction with 5-hydroxytryptamine3 receptors: in vivo and in vitro evidence. Journal of Pharmacology & Experimental Therapeutics. 1996;278(1):8–14
  14. Pickering G, Loriot MA, Libert F, et al. Analgesic effect of acetaminophen in humans: first evidence of a central serotonergic mechanism. Clinical Pharmacology and Therapeutics. 2006;79(4):371–378
  15. Ameer B, Divoll M, Abernethy DR, et al. Absolute and relative bioavailability of oral acetaminophen preparations. Journal of Pharmaceutical Sciences. 1983;72(8):955–958
  16. Holmer Pettersson P, Owall A, Jakobsson J. Early bioavailability of paracetamol after oral or intravenous administration. Acta Anaesthesiologica Scandinavica. 2004;48(7):867–870
  17. van Wyk M, Sommers DK, Meyer EC, Moncrieff J. The mean cumulative fraction absorbed-time profiles of paracetamol as an index of gastric emptying. Methods and Findings in Experimental and Clinical Pharmacology. 1990;12(4):291–294
  18. Lydon AM, Cooke T, Duggan F, et al. Delayed postoperative gastric emptying following intrathecal morphine and intrathecal bupivacaine. Canadian Journal of Anaesthesia. 1999;46(6):544–549
  19. Schuitmaker M, Anderson BJ, Holford NH, Woollard GA. Pharmacokinetics of paracetamol in adults after cardiac surgery. Anaesthesia and Intensive Care. 1999;27(6):615–622
  20. Feldman S. Bioavailability of acetaminophen suppositories. American Journal of Hospital Pharmacy. 1975;32(11):1173–1175
  21. Anderson BJ, Holford NH, Woollard GA, et al. Perioperative pharmacodynamics of acetaminophen analgesia in children. Anesthesiology. 1999;90(2):411–421
  22. Flouvat B, Leneveu A, Fitoussi S, et al. Bioequivalence study comparing a new paracetamol solution for injection and propacetamol after single intravenous infusion in healthy subjects. International Journal of Clinical Pharmacology and Therapeutics. 2004;42(1):50–57
  23. Szczurko C, Dompmartin A, Michel M, et al. Occupational contact dermatitis from propacetamol. Contact Dermatitis. 1996;35(5):299–301
  24. Moller PL, Juhl GI, Payen-Champenois C, Skoglund A. Intravenous acetaminophen (paracetamol): comparable analgesic efficacy, but better local safety than its prodrug, propacetamol, for postoperative pain after third molar surgery. Anesthesia and Analgesia. 2005;101(1):90–96
  25. Jarde O, Boccard E. Parenteral versus oral route increases paracetamol efficacy. Clinical Drug Investigation. 1997;14(6):474–481
  26. Moller PL, Sindet-Pedersen S, Petersen CT, et al. Onset of acetaminophen analgesia: comparison of oral and intravenous routes after third molar surgery. British Journal of Anaesthesia. 2005;94(5):642–648
  27. Pettersson PH, Jakobsson J, Owall A. Intravenous acetaminophen reduced the use of opioids compared with oral administration after coronary artery bypass grafting. Journal of Cardiothoracic and Vascular Anesthesia. 2005;19(3):306–309
  28. Lahtinen P, Kokki H, Hendolin H, et al. Propacetamol as adjunctive treatment for postoperative pain after cardiac surgery. Anesthesia and Analgesia. 2002;95(4):813–819
  29. Schug SA, Garrett WR, Gillespie G. Opioid and non-opioid analgesics. Best Practice & Research Clinical Anaesthesiology. 2003;17(1):91–110
  30. Graham GG, Scott KF, Day RO. Tolerability of paracetamol. Drug Safety. 2005;28(3):227–240
  31. Wallace CI, Dargan PI, Jones AL. Paracetamol overdose: an evidence based flowchart to guide management. Emergency Medicine Journal. 2002;19(3):202–205
  32. Kaplowitz N. Acetaminophen hepatoxicity: what do we know, what don't we know, and what do we do next?. Hepatology. 2004;40(1):23–26
  33. Rumack BH. Acetaminophen misconceptions. Hepatology. 2004;40(1):10–15
  34. Moling O, Cairon E, Rimenti G, et al. Severe hepatotoxicity after therapeutic doses of acetaminophen. Clinical Therapeutics. 2006;28(5):755–760
  35. Kurtovic J, Riordan SM. Paracetamol-induced hepatotoxicity at recommended dosage. Journal of Internal Medicine. 2003;253(2):240–243
  36. Munsterhjelm E, Munsterhjelm NM, Niemi TT, et al. Dose-dependent inhibition of platelet function by acetaminophen in healthy volunteers. Anesthesiology. 2005;103(4):712–717
  37. Clissold SP. Paracetamol and phenacetin. Drugs. 1986;32(supplement 4):46–59
  38. Avellaneda C, Gomez A, Martos F, et al. The effect of a single intravenous dose of metamizol 2g, ketorolac 30mg and propacetamol 1g on haemodynamic parameters and postoperative pain after heart surgery. European Journal of Anaesthesiology. 2000;17(2):85–90
  39. Hahn TW, Mogensen T, Lund C, et al. Analgesic effect of i.v. paracetamol: possible ceiling effect of paracetamol in postoperative pain. Acta Anaesthesiologica Scandinavica. 2003;47(2):138–145
  40. Moore A, Collins S, Carroll D, McQuay H. Paracetamol with and without codeine in acute pain: a quantitative systematic review. Pain. 1997;70(2-3):193–201
  41. Edwards JE, McQuay HJ, Moore RA. Combination analgesic efficacy: individual patient data meta-analysis of single-dose oral tramadol plus acetaminophen in acute postoperative pain. Journal of Pain and Symptom Management. 2002;23(2):121–130
  42. Schug SA, Sidebotham DA, McGuinnety M, et al. Acetaminophen as an adjunct to morphine by patient-controlled analgesia in the management of acute postoperative pain. Anesthesia and Analgesia. 1998;87(2):368–372
  43. Delbos A, Boccard E. The morphine-sparing effect of propacetamol in orthopedic postoperative pain. Journal of Pain and Symptom Management. 1995;10(4):279–286
  44. Koppert W, Wehrfritz A, Korber N, et al. The cyclooxygenase isozyme inhibitors parecoxib and paracetamol reduce central hyperalgesia in humans. Pain. 2004;108(1-2):148–153
  45. Remy C, Marret E, Bonnet F. Effects of acetaminophen on morphine side-effects and consumption after major surgery: meta-analysis of randomized controlled trials. British Journal of Anaesthesia. 2005;94(4):505–513
  46. Elia N, Lysakowski C, Tramer MR. Does multimodal analgesia with acetaminophen, nonsteroidal antiinflammatory drugs, or selective cyclooxygenase-2 inhibitors and patient-controlled analgesia morphine offer advantages over morphine alone? Meta-analyses of randomized trials. Anesthesiology. 2005;103(6):1296–1304
  47. Kvalsvik O, Borchgrevink PC, Hagen L, Dale O. Randomized, double-blind, placebo-controlled study of the effect of rectal paracetamol on morphine consumption after abdominal hysterectomy. Acta Anaesthesiologica Scandinavica. 2003;47(4):451–456
  48. Romsing J, Moiniche S, Dahl JB. Rectal and parenteral paracetamol, and paracetamol in combination with NSAIDs, for postoperative analgesia. British Journal of Anaesthesia. 2002;88(2):215–226
  49. Chandrasekharan NV, Dai H, Roos KL, et al. From the cover: COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proceedings of the National Academy of Sciences of the United States of America. 2002;99(21):13926–13931
  50. Hoigne R, Zoppi M, Sollberger J, et al. Fall in systolic blood pressure due to metamizol (dipyrone, noramidopyrine, novaminsulfone). Results from the Comprehensive Hospital Drug Monitoring Berne (CHDMB). Agents and Actions. Supplements. 1986;19:189–195
  51. Laporte JR, Carne X, Vidal X, et al. Upper gastrointestinal bleeding in relation to previous use of analgesics and non-steroidal anti-inflammatory drugs. Catalan Countries Study on Upper Gastrointestinal Bleeding. Lancet. 1991;337(8733):85–89
  52. Risk of anaphylaxis in a hospital population in relation to the use of various drugs: an international study. Pharmacoepidemiology and Drug Safety. 2003;12(3):195–202
  53. Sadusk JF. The relationship of the food and drug administration to the practice of medicine and the aminopyrine-dipyrone problem. The Journal of New Drugs. 1965;28:57–62
  54. Discombe G. Agranulocytosis caused by amidopyrine; an avoidable cause of death. British Medical Journal. 1952;1(4771):1270–1273
  55. Huguley CM. Agranulocytosis Induced by Dipyrone, a Hazardous Antipyretic and Analgesic. JAMA. 1964;189:938–941
  56. Kelly JP, Kaufman DW, Shapiro S. Risks of agranulocytosis and aplastic anemia in relation to the use of cardiovascular drugs: the International Agranulocytosis and Aplastic Anemia Study. Clinical Pharmacology and Therapeutics. 1991;49(3):330–341
  57. Shapiro S, Issaragrisil S, Kaufman DW, et al. Agranulocytosis in Bangkok, Thailand: a predominantly drug-induced disease with an unusually low incidence. Aplastic Anemia Study Group. The American Journal of Tropical Medicine and Hygiene. 1999;60(4):573–577
  58. Ibanez L, Vidal X, Ballarin E, Laporte JR. Agranulocytosis associated with dipyrone (metamizol). European Journal of Clinical Pharmacology. 2005;60(11):821–829
  59. Maj S, Centkowski P. A prospective study of the incidence of agranulocytosis and aplastic anemia associated with the oral use of metamizole sodium in Poland. Medical Science Monitor. 2004;10(9):PI93–PI95
  60. Hedenmalm K, Spigset O. Agranulocytosis and other blood dyscrasias associated with dipyrone (metamizole). European Journal of Clinical Pharmacology. 2002;58(4):265–274
  61. Vlahov V, Bacracheva N, Tontcheva D, et al. Genetic factors and risk of agranulocytosis from metamizol. Pharmacogenetics. 1996;6(1):67–72
  62. Ibanez L, Vidal X, Ballarin E, Laporte JR. Population-based drug-induced agranulocytosis. Archives of Internal Medicine. 2005;165(8):869–874
  63. Andrade SE, Martinez C, Walker AM. Comparative safety evaluation of non-narcotic analgesics. Journal of Clinical Epidemiology. 1998;51(12):1357–1365
  64. Wong A. A reappraisal of antipyretic and analgesic drugs. WHO Pharmaceutical Newsletter. 2002;1:15–16
  65. Edwards JE, Meseguer F, Faura CC, et al. Single-dose dipyrone for acute postoperative pain. Cochrane Database of Systematic Reviews. 2001;(3):CD003227
  66. Grundmann U, Wornle C, Biedler A, et al. The efficacy of the non-opioid analgesics parecoxib, paracetamol and metamizol for postoperative pain relief after lumbar microdiscectomy. Anesthesia and Analgesia. 2006;103(1):217–222
  67. Steffen P, Schuhmacher I, Weichel T, et al. Differential administration of non-opioids in postoperative analgesia, I. Quantification of the analgesic effect of metamizole using patient-controlled analgesia. Anästhesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie. 1996;31(3):143–147
  68. Kampe S, Warm M, Landwehr S, et al. Clinical equivalence of IV paracetamol compared to IV dipyrone for postoperative analgesia after surgery for breast cancer. Current Medical Research and Opinion. 2006;22(10):1949–1954
  69. Oberhofer D, Skok J, Nesek-Adam V. Intravenous ketoprofen in postoperative pain treatment after major abdominal surgery. World Journal of Surgery. 2005;29(4):446–449
  70. Kessler W, Kirchhoff C, Reeh PW, Handworker HO. Excitation of cutaneous afferent nerve endings in vitro by a combination of inflammatory mediators and conditioning effect of substance P. Experimental Brain Research. 1992;91(3):467–476
  71. Woolf PC. Recent advances in the pathophysiology of acute pain. British Journal of Anaesthesia. 1989;63:139–146
  72. Harris SI, Kuss M, Hubbard RC, Goldstein JL. Upper gastrointestinal safety evaluation of parecoxib sodium, a new parenteral cyclooxygenase-2-specific inhibitor, compared with ketorolac, naproxen, and placebo. Clinical Therapeutics. 2001;23(9):1422–1428
  73. Stoltz RR, Harris SI, Kuss ME, et al. Upper GI mucosal effects of parecoxib sodium in healthy elderly subjects. The American Journal of Gastroenterology. 2002;97(1):65–71
  74. Cheng HF, Harris RC. Renal effects of non-steroidal anti-inflammatory drugs and selective cyclooxygenase-2 inhibitors. Current Pharmaceutical Design. 2005;11(14):1795–1804
  75. Lee A, Cooper MC, Craig JC, et al. Effects of nonsteroidal anti-inflammatory drugs on postoperative renal function in adults with normal renal function. Cochrane Database of Systematic Reviews. 2004;(2):CD002765
  76. Weir MR. Renal effects of nonselective NSAIDs and coxibs. Cleveland Clinic Journal of Medicine. 2002;69(supplement 1):SI53–SI58
  77. Rubenstein JH, Laine L. Systematic review: the hepatotoxicity of non-steroidal anti-inflammatory drugs. Alimentary Pharmacology & Therapeutics. 2004;20(4):373–380
  78. Nielsen JD, Holm-Nielsen A, Jespersen J, et al. The effect of low-dose acetylsalicylic acid on bleeding after transurethral prostatectomy–a prospective, randomized, double-blind, placebo-controlled study. Scandinavian Journal of Urology and Nephrology. 2000;34(3):194–198
  79. Ferraris VA, Ferraris SP, Joseph O, et al. Aspirin and postoperative bleeding after coronary artery bypass grafting. Annals of Surgery. 2002;235(6):820–827
  80. Hegi TR, Bombeli T, Seifert B, et al. Effect of rofecoxib on platelet aggregation and blood loss in gynaecological and breast surgery compared with diclofenac. British Journal of Anaesthesia. 2004;92(4):523–531
  81. Moiniche S, Romsing J, Dahl JB, Tramer MR. Nonsteroidal antiinflammatory drugs and the risk of operative site bleeding after tonsillectomy: a quantitative systematic review. Anesthesia and Analgesia. 2003;96(1):68–77(table of contents)
  82. Johnsen SP, Larsson H, Tarone RE, et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Archives of Internal Medicine. 2005;165(9):978–984
  83. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet. 2005;365(9458):475–481
  84. Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006;332(7553):1302–1308
  85. Australian and New Zealand College of Anaesthetists , Faculty of Pain Medicine . Acute pain management: scientific evidence. 2nd ed.. Melbourne: Australian and New Zealand College of Anaesthetists; 2005;
  86. Reuben SS, Buvanendran A, Kroin JS, Steinberg RB. Postoperative modulation of central nervous system prostaglandin E2 by cyclooxygenase inhibitors after vascular surgery. Anesthesiology. 2006;104(3):411–416
  87. Cheer SM, Goa KL. Parecoxib (parecoxib sodium). Drugs. 2001;61(8):1133–1141
  88. Daniels SE, Grossman EH, Kuss ME, et al. A double-blind, randomized comparison of intramuscularly and intravenously administered parecoxib sodium versus ketorolac and placebo in a post-oral surgery pain model. Clinical Therapeutics. 2001;23(7):1018–1031
  89. Glassman SD, Rose SM, Dimar JR, et al. The effect of postoperative nonsteroidal anti-inflammatory drug administration on spinal fusion. Spine. 1998;23(7):834–838
  90. Reuben SS, Ablett D, Kaye R. High dose nonsteroidal anti-inflammatory drugs compromise spinal fusion. Canadian Journal of Anaesthesia. 2005;52(5):506–512
  91. Reuben SS, Ekman EF. The effect of cyclooxygenase-2 inhibition on analgesia and spinal fusion. The Journal of Bone and Joint Surgery. American Volume. 2005;87(3):536–542
  92. Gyllfors P, Bochenek G, Overholt J, et al. Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase 2-selective analgetic drug celecoxib. The Journal of Allergy and Clinical Immunology. 2003;111(5):1116–1121
  93. Martin-Garcia C, Hinojosa M, Berges P, et al. Celecoxib, a highly selective COX-2 inhibitor, is safe in aspirin-induced asthma patients. Journal of Investigational Allergology & Clinical Immunology. 2003;13(1):20–25
  94. Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. The New England Journal of Medicine. 2005;352(11):1081–1091
  95. Borgdorff P, Tangelder GJ, Paulus WJ. Cyclooxygenase-2 inhibitors enhance shear stress-induced platelet aggregation. Journal of the American College of Cardiology. 2006;48(4):817–823
  96. Maxwell M, Nathanson M. Parecoxib - getting to the heart of the matter. Anaesthesia. 2006;61(9):823–825
  97. Nussmeier NA, Whelton AA, Brown MT, et al. Safety and efficacy of the cyclooxygenase-2 inhibitors parecoxib and valdecoxib after noncardiac surgery. Anesthesiology. 2006;104(3):518–526
  98. Schug SA, Camu F, Joshi GP. Cardiovascular safety of the cyclooxygenase-2 selective inhibitor parecoxib sodium: review of pooled data from surgical studies. European Journal of Anaesthesiology. 2006;23(supplement 37):219
  99. Barden J, Edwards JE, McQuay HJ, Moore RA. Oral valdecoxib and injected parecoxib for acute postoperative pain: a quantitative systematic review. BMC Anesthesiology. 2003;3(1):1
  100. Gan TJ, Joshi GP, Zhao SZ, et al. Presurgical intravenous parecoxib sodium and follow-up oral valdecoxib for pain management after laparoscopic cholecystectomy surgery reduces opioid requirements and opioid-related adverse effects. Acta Anaesthesiologica Scandinavica. 2004;48(9):1194–1207
  101. Gan TJ, Joshi GP, Viscusi E, et al. Preoperative parenteral parecoxib and follow-up oral valdecoxib reduce length of stay and improve quality of patient recovery after laparoscopic cholecystectomy surgery. Anesthesia and Analgesia. 2004;98(6):1665–1673

PII: S1521-6896(06)00083-8

doi: 10.1016/j.bpa.2006.12.002

Best Practice & Research Clinical Anaesthesiology
Volume 21, Issue 1 , Pages 15-30 , March 2007

Article Tools